Pf 477736

Manufactured by AbMole

PF-477736 is a chemical compound used in research laboratory settings. It functions as a selective inhibitor, targeting specific molecular pathways. The core purpose of this product is to facilitate scientific investigation and experimentation within controlled environments.

Automatically generated - may contain errors

Lab products found in correlation

Ve 822, by AbMole (2 mentions) Nod scid il2rgammanull mice, by Jackson ImmunoResearch (1 mentions) Azd6738, by Selleck Chemicals (1 mentions)

3 protocols using pf 477736

Comparison of ATR and Chk1 Inhibitors in Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

The ATR inhibitor VE-822 (Abmole, M3115) was dissolved in an equilibrated (v/v) mixture of PBS (70%), Polyethylene glycol 300 (PEG300, 29.5%) and Tween 80 (0.5%) at a concentration of 18.0 mg/ml. The Chk1 inhibitor PF-477736 (Abmole, M1764) was prepared in a 1:1 (v/v) mixture of PBS and dimethyl sulfoxide at a concentration of 10.0 mg/ml. The following treatment regimens were applied in the allograft and the xenograft mouse model:

Control cohort: daily intraperitoneal injection of PBS/DMSO vehicle solution.

VE-822 cohort: weekly for three consecutive days at a dose of 30 mg/kg by oral gavage.

PF-477736 cohort: weekly for five consecutive days at a dose of 20 mg/kg by intraperitoneal injection.

Doerr F., George J., Schmitt A., Beleggia F., Rehkämper T., Hermann S., Walter V., Weber J.P., Thomas R.K., Wittersheim M., Büttner R., Persigehl T, & Reinhardt H.C. (2017). Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Scientific Reports, 7, 15511.

+ Open protocol

+ Expand

Chk1 Inhibition Impairs Myeloma Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal studies were IACUC approved and performed in accordance with AAALAC, USDA, and PHS guidelines. NOD-SCID IL2Rgamma^null mice (Jackson Laboratories, Bar Harbor, ME) were subcutaneously injected with 5 × 10⁶ U266 cells into the flank. The Chk1 inhibitor PF-477736 (Abmole, M1764) was prepared in a 1:1 (v/v) mixture of PBS and dimethyl sulfoxide at a concentration of 10.0 mg/ml. When tumors grew to 300 mm³, PF (15 mg/kg per day) was administrated (i.p.) for 3 days. Control animals received equal volumes of vehicle. Tumors were collected to perform immunoblotting and immunohistochemistry staining.
For additional information and methods, see Supplementary Materials and Methods, and Supplemental Table 1.

Zhou L., Pei X., Zhang Y., Ning Y., Li L., Hu X., Chalasani S.L., Sharma K., Nkwocha J., Yu J., Bandyopadhyay D., Sebti S.M, & Grant S. (2022). Chk1 inhibition potently blocks STAT3 tyrosine705 phosphorylation, DNA binding activity, and activation of downstream targets in human multiple myeloma cells. Molecular cancer research : MCR, 20(3), 456-467.

+ Open protocol

+ Expand

Small molecule inhibitor protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cisplatin was purchased from Accord Pharmaceuticals and etoposide was from Hexal Pharma. VE-822 and PF-477736, as well as AZD-7762 were purchased from Abmole and AZD-6738 was from Selleckchem. All small molecule compounds were dissolved in DMSO and stored at −80 °C or −20 °C, according to instructions.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!